Sadhana Nitro Chem Q1 FY27: Revenue ₹27.22 cr, loss ₹0.55 cr

Board clears Q1 numbers and share issue

Sadhana Nitro Chem Limited said its Board of Directors met on August 7, 2026, to approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 (Q1 FY27). The board also authorised a preferential issue of equity shares. The update covers both the parent company’s standalone performance and the consolidated view that includes its subsidiary, Anuchem B.V.B.A, Belgium. The company disclosed revenue and net loss figures for the quarter, along with sequential and year-on-year changes for key standalone items. It also provided details on how its paid-up equity share capital changed following earlier fund-raising actions and the proposed allotment.

Standalone performance: revenue rises sequentially, loss narrows

On a standalone basis, revenue from operations in Q1 FY27 stood at ₹26.18 crore (₹2,618 lakh). The company said this represented a 302.15% sequential increase compared with ₹6.51 crore (₹651 lakh) in Q4 FY26. On a year-on-year basis, revenue was down 6.83% from ₹28.10 crore (₹2,810 lakh) in Q1 FY26.

Sadhana Nitro Chem reported a standalone net loss after tax of ₹0.40 crore (₹40 lakh) for Q1 FY27. The company reported a sharp improvement compared with a net loss of ₹33.83 crore (₹3,383 lakh) in Q4 FY26. It also reported an improvement versus the net loss of ₹1.70 crore (₹170 lakh) in Q1 FY26.

Consolidated performance includes Belgian subsidiary

On a consolidated basis, revenue for Q1 FY27 was reported at ₹27.22 crore (₹2,722 lakh). Consolidated net loss after tax was ₹0.55 crore (₹55 lakh) for the quarter. The company stated that the consolidated results include Anuchem B.V.B.A, Belgium.

The company’s disclosure did not provide the same detailed QoQ and YoY percentage breakdown for the consolidated line items that it gave for standalone revenue and standalone net loss after tax. Investors typically track the difference between standalone and consolidated performance to understand the contribution and cost structure of subsidiaries, particularly when a foreign subsidiary is part of the group reporting.

Preferential allotment: 67.5 crore shares at ₹2.06

The board approved a preferential allotment of 6,75,00,000 equity shares at ₹2.06 per share. The company has also described this preferential allotment as designed to raise approximately ₹13.90 crore.

Separately, the company has disclosed that it received in-principle approval from BSE and NSE in relation to the proposed preferential allotment. The approval referenced is an exchange-related step and does not, by itself, describe the timing of allotment completion.

Paid-up equity capital movement after allotment

Sadhana Nitro Chem disclosed that its paid-up equity share capital increased from ₹296,46,94,385 to ₹303,21,94,385 post-allotment. In crore terms, that is an increase from about ₹296.47 crore to about ₹303.22 crore.

The company has also previously disclosed a large rights issue allotment. The Rights Issue Committee approved allotment on March 12, 2026, under which 263,52,83,328 fully paid-up equity shares were allotted at ₹1 per share. Following that rights issue, the paid-up equity capital increased from ₹32,94,11,057 to ₹2,96,46,94,385. The company also stated that rights issue proceeds of ₹251.95 crore were utilised for the objects of the issue as contained in the Letter of Offer till March 31, 2026.

Key numbers at a glance

FY26 context: sharp swing to loss

For the financial year ended March 31, 2026, Sadhana Nitro Chem reported a net loss of ₹873.1 crore, compared with a net profit of ₹52.2 crore in FY25. The board approved audited standalone and consolidated financial results on May 26, 2026, and decided not to recommend a dividend for the year.

The company also reported that for the quarter ended March 31, 2026 (Q4 FY26), it posted a net loss of ₹33.83 crore on revenue of ₹6.51 crore. These reported Q4 FY26 figures are consistent with the standalone comparative numbers referenced in the Q1 FY27 update.

Market snapshot cited in disclosures

In the material provided alongside these updates, the stock price was cited at ₹2.87, with 1-year returns of -67.86%. The same set of information also referenced an open price of ₹2.97 and a previous close of ₹2.92.

These data points provide context for how the market has valued the company during a period that included significant capital actions and a sharp reported loss for FY26. However, the company’s Q1 FY27 filing itself focuses on the financial results and the preferential allotment approvals.

Why this update matters

Two elements stand out in the Q1 FY27 announcement. First, standalone revenue rose sharply versus Q4 FY26, and the standalone net loss narrowed substantially on both a sequential and year-on-year basis. Second, the company continues to execute capital-raising and capital-structure actions, including a preferential issue at ₹2.06 per share.

The combination of quarterly operating numbers and equity issuance details is relevant because it influences per-share metrics, cash availability for operations, and how investors interpret the path from losses toward improved financial stability. The company has also disclosed that it entered into a long-term supply contract with a Japanese multinational customer for the export of a speciality chemical product, which forms part of the broader business context mentioned in its updates.

Capital actions summary

Conclusion

Sadhana Nitro Chem’s Q1 FY27 update shows standalone revenue of ₹26.18 crore and a standalone net loss of ₹0.40 crore, while consolidated revenue was ₹27.22 crore with a consolidated net loss of ₹0.55 crore. Alongside the quarterly numbers, the board-approved preferential allotment of 6.75 crore shares at ₹2.06 per share is a key corporate action that changes the paid-up equity capital base. The next set of confirmations for investors will be linked to the company’s regulatory filings and any further disclosures on the completion and utilisation of proceeds from the preferential allotment.